Dynavax Technologies (DVAX) Statistics

Dynavax Technologies Corp (DVAX) is a biopharmaceutical company dedicated to developing and commercializing innovative vaccines to prevent and treat infectious diseases. As of the latest statistics, DVAX stock has a market capitalization of $1.83 billion and a 52-week high of $27.90. The stock has shown strong performance, outperforming the sector by an impressive margin. In terms of valuation metrics, DVAX has a price-to-earnings ratio of -4.33, indicating that the company is currently operating at a loss.

The fundamentals of Dynavax Technologies Corp are promising. The company has a solid revenue per share of $12.17, demonstrating its ability to generate income. Additionally, its enterprise to EBITDA ratio stands at -5.10, indicating a strong cash flow and financial stability. DVAX also boasts a healthy profit margin of -481.11%, showing significant potential for profitability in the future. Notably, the company has managed to keep its total debt at a manageable level of $50 million, ensuring a sustainable financial position. Lastly, Dynavax Technologies Corp has achieved a gross profit of $1.25 billion, reflecting its ability to generate substantial revenue.